Health
Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD
Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…
-
Noosa News14 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business16 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
General16 hours agoDay of pain: sirens ring out to mark attack on Israel
-
Business18 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today